Zepbound for PCOS: What Insurance Actually Covers and What You Will Really Pay

What "Off-Label" Actually Means for Your Pharmacy Bill

Off-label means the FDA has not reviewed tirzepatide specifically for PCOS. Your prescriber can write the script legally, but your insurance company reads the diagnosis code and decides whether to pay. That distinction costs real money.

When a drug is on-label, insurers follow FDA guidance. When it is off-label, they write their own rules, and those rules almost always start from a position of denial. For Zepbound and PCOS, the diagnosis code your provider submits (most commonly E28.2 for polycystic ovarian syndrome) is not on Lilly's FDA-approved label, which lists obesity (E66) and weight-related comorbidities. Many plans therefore route your claim through their weight-management exclusion rather than their endocrine or reproductive-health benefit.

PCOS affects an estimated 8 to 13 percent of reproductive-age women worldwide, making it the most common endocrine disorder in women of reproductive age. Despite its metabolic core, it has no FDA-approved pharmacotherapy targeting the syndrome as a whole. That regulatory gap is a direct driver of the coverage problem you are facing.

Why the Obesity Label Creates a Coverage Trap

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. The label lists type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease as qualifying comorbidities. PCOS is not named.

Because PCOS is not named, and because the drug is approved under a weight category, most pharmacy benefit managers (PBMs) flag tirzepatide as a "weight loss medication." The Employee Retirement Income Security Act (ERISA) allows self-insured employer plans to exclude entire drug categories, and weight-loss drugs have been the most commonly excluded category for decades. An estimated fewer than 30 percent of large employer plans covered any anti-obesity medication as of 2023.

When PCOS Qualifies as a Comorbidity Anyway

Here is where a careful prior authorization strategy can shift the outcome. If you have a BMI of 27 or higher and a documented insulin-resistance or metabolic component to your PCOS, your provider can frame the request around the on-label comorbidity pathway. Insulin resistance is present in approximately 65 to 70 percent of women with PCOS, and dyslipidemia is a recognized comorbidity on the Zepbound label. Submitting labs that document elevated fasting insulin, triglycerides, or impaired glucose tolerance gives the prior-auth reviewer a hook that does not require off-label justification.

This framing does not change the drug or the dose. It changes the diagnostic story on the form.

The Real Numbers: What Zepbound Costs Without Full Coverage

List price matters because it is the number you pay when coverage fails. Eli Lilly set the monthly list price for Zepbound at approximately $1,059.87 for the four-pen starter dose (2.5 mg). Maintenance doses at 10 mg, 12.5 mg, or 15 mg cost more per box.

The Lilly Savings Card (Commercial Insurance)

Eli Lilly offers a savings card program for Zepbound through LillyDirect. Commercially insured patients who meet eligibility criteria can pay as little as $25 per month. The card is not available to Medicare or Medicaid patients. Income thresholds and plan-type restrictions apply and change without much notice, so verify eligibility each fill cycle.

Patients whose plans technically cover Zepbound but apply high cost-sharing may find the card reduces their copay to $25. Patients whose plans deny Zepbound entirely may still qualify for the uninsured rate card, which typically caps monthly out-of-pocket at $550 or less, though that number has fluctuated with demand.

Compounded Tirzepatide: Lower Cost, Real Legal Risk

Because tirzepatide appeared on the FDA's drug shortage list from 2023 into early 2025, compounding pharmacies were legally permitted to produce tirzepatide formulations. Compounded tirzepatide from a 503A pharmacy (patient-specific) or a 503B outsourcing facility has been available for $200 to $600 per month in many markets, representing a significant savings over brand-name Zepbound.

The FDA removed tirzepatide from its shortage list in early 2025, which means compounding pharmacies' legal authority to produce it is narrowing. State enforcement timelines vary. If you are currently using a compounded product, discuss with your provider how the supply picture affects your access and whether transitioning to brand Zepbound with a savings card makes more financial sense now.

Compounded products are not FDA-evaluated for potency, sterility, or bioequivalence. The clinical trial data you will read about in prior-auth letters and appeals was generated on Lilly's proprietary formulation, not on compounded versions.

Medicare and Medicaid: The Hard Limits

Medicare Part D is prohibited by statute from covering drugs approved solely for weight loss, under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Because Zepbound's primary approval is obesity, Part D plans cannot cover it for most members. A 2024 pilot program under the Inflation Reduction Act proposed expanding coverage, but implementation for anti-obesity medications remains limited as of early 2025. If you are post-menopausal and on Medicare, your out-of-pocket exposure is the full list price minus any manufacturer assistance you qualify for, which is almost certainly zero under Medicare rules.

Medicaid coverage is state-by-state. A small number of states, including California and Colorado, have added anti-obesity medication coverage to their Medicaid formularies. Most have not. Check your state Medicaid formulary directly; the answer changes annually.

Navigating Prior Authorization for PCOS

Prior authorization (PA) for Zepbound in a PCOS context is almost universal. A denial on the first submission is common and should not be read as a final answer.

What a Strong PA Submission Includes

Your provider's office should submit:

• A detailed clinical letter explaining why tirzepatide addresses the specific metabolic mechanisms driving your PCOS (insulin resistance, hyperandrogenism, anovulation)
• Lab documentation: fasting insulin, glucose, HbA1c, testosterone (free and total), LH/FSH ratio, lipid panel
• History of prior treatments and their outcomes: metformin trials, weight-loss attempts, clomiphene or letrozole if fertility was a goal
• BMI at the time of the request, and any comorbidities that appear on the Zepbound label (dyslipidemia, impaired fasting glucose)
• Published literature linking tirzepatide's GIP and GLP-1 dual agonism to improvements in PCOS endpoints. The SURMOUNT-1 trial demonstrated 20.9 percent mean body-weight reduction at 72 weeks with 15 mg tirzepatide in adults with obesity, and subgroup data suggest metabolic improvements that are directly relevant to PCOS pathophysiology.

The Appeal Process

If the PA is denied, you have the right to an internal appeal and, in most states, an external independent review. Your provider should write the appeal letter, not leave it to the insurer's template. The letter should cite the absence of FDA-approved therapies for PCOS as a systemic coverage gap, reference the American Society for Reproductive Medicine's acknowledgment that weight loss improves reproductive and metabolic outcomes in PCOS, and frame denial as a sex-specific coverage disparity.

A three-tier appeal framework that has worked in clinical practice at WomanRx:

Tier 1 (Internal appeal): Submit within 60 days of denial. Include peer-reviewed literature and clinical letter. Target: plan's medical director, not the PA reviewer.

Tier 2 (External independent review): Request this simultaneously or after Tier 1 denial. An independent physician reviewer must assess the case without plan bias.

Tier 3 (State insurance commissioner complaint): If the external review still denies, filing a complaint with your state commissioner creates a paper trail and sometimes prompts reconsideration, particularly in states with mental-health and endocrine parity regulations that may apply to PCOS.

Sex-Specific Physiology: Why Tirzepatide Works Differently in Women with PCOS

PCOS is not simply an ovarian condition. Its metabolic drivers, including hyperinsulinemia, elevated androgens, and chronic low-grade inflammation, create a feedback loop that standard weight-loss advice does not break efficiently.

Tirzepatide acts on two incretin receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In women with PCOS, GLP-1 receptor agonists have already shown meaningful effects. A 2022 systematic review in Fertility and Sterility found that GLP-1 receptor agonists reduced testosterone levels, improved menstrual regularity, and decreased fasting insulin in women with PCOS, independent of weight loss. Tirzepatide's additional GIP agonism may amplify these effects through complementary pathways, though direct PCOS-specific trial data for tirzepatide remain limited. Women have been underrepresented in the SURMOUNT trial substratifications by reproductive diagnosis, which is a genuine evidence gap.

Body fat distribution also matters. Women with PCOS carry disproportionately more visceral adiposity relative to their BMI compared with weight-matched women without PCOS. Visceral fat is the primary driver of insulin resistance in PCOS, and tirzepatide has demonstrated preferential reduction in visceral fat in its trial populations. This means a woman with PCOS may derive metabolic benefit at a lower absolute weight loss than the aggregate trial data suggest.

Pharmacokinetically, tirzepatide's half-life of approximately five days means once-weekly dosing applies equally across sexes, but body weight affects total exposure. Women with lower body weight reach higher plasma concentrations per dose, which may mean better efficacy at lower doses and potentially greater nausea at initiation. Starting at 2.5 mg and titrating slowly is particularly important.

Pregnancy, Lactation, and Contraception: Required Reading Before You Start

Zepbound is contraindicated in pregnancy. This is not a nuanced risk-benefit discussion for the majority of women. The FDA label carries a precautionary contraindication because animal studies at clinically relevant exposures showed embryo-fetal toxicity, and there are no adequate human pregnancy data.

The FDA Zepbound prescribing information states that tirzepatide should be discontinued at least two months before a planned pregnancy, given its five-day half-life and time to clearance. Because many women with PCOS are trying to conceive, this creates a specific clinical decision point.

Contraception While Using Zepbound

If you are sexually active and not actively trying to conceive, use effective contraception throughout tirzepatide treatment. Oral contraceptives are commonly co-prescribed in PCOS for cycle regulation and androgen suppression, and the interaction is clinically relevant: tirzepatide slows gastric emptying, which may reduce peak plasma concentrations of oral contraceptive pills, particularly in the first four weeks after starting or dose-escalating. ACOG recommends a backup contraceptive method for at least four weeks after starting or dose-escalating a GLP-1 or GIP/GLP-1 agonist if you rely on oral contraceptives. A patch, ring, IUD, or implant avoids this interaction entirely.

If Your Goal Is to Conceive

Tirzepatide may improve ovulatory function by reducing insulin resistance and androgen levels. Pregnancy has occurred in women using GLP-1-class drugs who did not expect to ovulate. This is a wanted outcome if you are trying to conceive, but the drug must be stopped before or at the moment of confirmed pregnancy. Work with your reproductive endocrinologist or OB-GYN to establish a clear stop protocol before you begin.

Lactation

No human lactation data exist for tirzepatide. Animal studies suggest transfer into milk. Given the absence of safety data and tirzepatide's molecular weight and mechanism, most clinicians advise against use during breastfeeding. The postpartum period is also a time of rapid hormonal flux; PCOS symptoms often shift after delivery, and the risk-benefit calculation should be reassessed with your provider at each postpartum visit.

Who This Drug Is Right For, and Who Should Wait

Women Most Likely to Benefit

• Reproductive-age women with PCOS, a BMI of 27 or higher, documented insulin resistance, and at least one metabolic comorbidity
• Women who have used metformin and experienced GI intolerance or inadequate response
• Women with anovulatory cycles who are not currently trying to conceive and want to improve cycle regularity
• Perimenopausal women with PCOS whose metabolic symptoms are amplifying with the hormonal changes of the menopause transition (estrogen decline worsens insulin sensitivity, compounding PCOS-related metabolic burden)

Women Who Should Not Start Now

• Pregnant women or women who plan to become pregnant within two months
• Breastfeeding women
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), as the FDA label carries a boxed warning for this risk
• Women with a history of pancreatitis (use with caution; discuss with your provider)
• Women under 18 (no pediatric data for this indication)

Perimenopause and Post-Menopause

PCOS does not resolve at menopause. The hyperandrogenism and metabolic risk persist, and postmenopausal women with PCOS carry elevated cardiovascular risk. If you are postmenopausal with persistent metabolic PCOS features and a qualifying BMI, the on-label obesity indication may apply directly, making the coverage argument easier and the clinical case straightforward. The challenge remains Medicare's statutory exclusion if you are 65 or older.

Practical Steps: Getting Started Without Paying Full Price

1. Get a complete metabolic workup first. Fasting insulin, HbA1c, lipid panel, free and total testosterone, and pelvic ultrasound if not recently done. These labs build your PA case and document comorbidities that matter to the insurer.

2. Ask your provider to submit under the most defensible primary diagnosis. If your BMI qualifies and you have dyslipidemia or impaired fasting glucose, an on-label framing may succeed where a pure PCOS framing fails.

3. Apply for the Lilly savings card immediately. Do this before or at the time of your first fill. The card takes minutes to activate and can cut your monthly cost dramatically if you have commercial insurance or even if you are uninsured.

4. If you are denied, appeal within 60 days. Do not accept the first denial as the end of the conversation.

5. Ask your provider about a compounded alternative while your appeal is active. If tirzepatide remains shortage-listed in your state, this may be a legal bridge option at lower cost.

6. Check employer HR if you have an employer-sponsored plan. Some employers have added anti-obesity medication coverage in 2024 and 2025 in response to workforce demand. The answer on your plan may have changed since your last enrollment cycle.